Efficacy and safety of tofacitinib in rheumatoid arthritis: Nine years of real‐world data

Autor:	Ali Ekin, Salim Misirci, Selin İldemir, Belkıs Nihan Coskun, Burcu Yagiz, Ediz Dalkilic, Yavuz Pehlivan
Jazyk:	angličtina
Rok vydání:	2024
Předmět:	Therapeutics. Pharmacology RM1-950 Public aspects of medicine RA1-1270
Zdroj:	Clinical and Translational Science, Vol 17, Iss 11, Pp n/a-n/a (2024)
Druh dokumentu:	article
ISSN:	1752-8062 1752-8054 04980654
DOI:	10.1111/cts.70084
Popis:	Abstract Tofacitinib is a targeted JAK inhibitor used to treat rheumatoid arthritis. Despite some recent safety concerns, it is considered effective and safe with appropriate patient selection. Between May 2015 and May 2024, data were retrospectively analyzed from 112 patients with a diagnosis of RA in a tertiary care hospital who had received tofacitinib for at least 1 month, with or without prior biologic DMARDs. The mean disease duration was 12 years, and the median duration of tofacitinib use was 32.5 months. The p‐value for all disease activity parameters evaluated for effectiveness between the 1st‐ and 3rd‐month visits was
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/71c8c049806549e785c955197f552ccc Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.